Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
32 results about "Arg-Gly-Asp-Val" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
RGD peptide-modified carbolino-hexahydropyrazine-1,4-diketones and their preparation method, antithrombotic effect and use
InactiveCN103450334AOrganic active ingredientsPeptide preparation methodsDiketoneAntithrombotic Agent
The invention discloses RGD peptide-modified carbolino-hexahydropyrazine-1,4-diketones, which are three novel conjugates of carbolino-hexahydropyrazine-1,4-diketone and RGD tetrapeptide and are shown in the general formula I. In the general formula I, R represents Arg-Gly-Asp-Val, Arg-Gly-Asp-Phe or Arg-Gly-Asp-Ser. The invention also discloses heterocyclic nucleuses of the novel conjugates, wherein R represents OH. The invention also discloses a preparation method and in-vitro anti-platelet aggregation effects of the novel conjugates, and also discloses an antithrombotic use of the novel conjugates in a rat thrombus formation model. A result shows that the three novel conjugates of carbolino-hexahydropyrazine-1,4-diketone and RGD tetrapeptide (wherein R represents Arg-Gly-Asp-Val, Arg-Gly-Asp-Phe or Arg-Gly-Asp-Ser) and their heterocyclic nucleuses (wherein R represents OH) have good antithrombotic activity and clear application prospects in antithrombotic agent preparation.
Owner:CAPITAL UNIVERSITY OF MEDICAL SCIENCES
Lys and oligopeptide-modified curcumin derivatives, and synthesis and medical application thereof
The present invention discloses six pseudo-peptides of the general formula I, wherein R1 is H or CH3, and R2 is Lys or Lys (Pro-Ala-Lys)-Arg-Gly-Asp-Val or Lys (Pro-Ala-Lys)-Ala-Gly-Asp-Val. The present invention further discloses a preparation method and use thereof. The compounds of the present invention have excellent thrombolytic activity, antithrombotic activity, anti-inflammatory activity, and OH radical scavenging activity, and a nanostructure.
Owner:CAPITAL UNIVERSITY OF MEDICAL SCIENCES
Warfarin-4-O-acetyl-RGD tetrapeptides, synthesis, activities and applications thereof
InactiveCN107488212AReduce bleeding riskTetrapeptide ingredientsPeptide preparation methodsArg-Gly-Asp-PheIn vivo
The present invention discloses three materials such as warfarin-4-O-acetyl-Arg-Gly-Asp-Val, warfarin-4-O-acetyl-Arg-Gly-Asp-Ser and warfarin-4-O-acetyl-Arg-Gly-Asp-Phe, preparation methods, anti-arterial thrombus activities, anti-venous thrombosis activities, in vivo vitamin K content lowering activities, in vivo blood coagulation factor II content lowering activities, platelet aggregation inhibition activities thereof, and in vivo platelet membrane glycoprotein IIb / IIIa (GPIIb / IIIa) content lowering activities thereof, and discloses the advantages of no warfarin-like bleeding risk in warfarin-4-O-acetyl-Arg-Gly-Asp-Val, warfarin-4-O-acetyl-Arg-Gly-Asp-Ser and warfarin-4-O-acetyl-Arg-Gly-Asp-Phe, such that the invention discloses applications of warfarin-4-O-acetyl-Arg-Gly-Asp-Val, warfarin-4-O-acetyl-Arg-Gly-Asp-Ser and warfarin-4-O-acetyl-Arg-Gly-Asp-Phe in preparation of anti-arterial thrombus drugs, anti-venous thrombosis drugs, platelet aggregation inhibition drugs, GPIIb / IIIa antagonists, vitamin K antagonists, and blood coagulation factor II antagonists.
Owner:CAPITAL UNIVERSITY OF MEDICAL SCIENCES
KRGD peptide-modified carbolino-hexahydropyrazine-1,4-diketones and their preparation method, antithrombotic effect and use
InactiveCN103450336AOrganic active ingredientsPeptide preparation methodsAntithrombotic AgentDiketone
The invention discloses KRGD peptide-modified carbolino-hexahydropyrazine-1,4-diketones, which are three novel conjugates of carbolino-hexahydropyrazine-1,4-diketone and RGD peptide and are shown in the general formula I. In the general formula I, R represents Lys-Arg-Gly-Asp-Val, Lys-Arg-Gly-Asp-Phe or Lys-Arg-Gly-Asp-Ser. The invention also discloses heterocyclic nucleuses of the novel conjugates, wherein R represents OH. The invention also discloses a preparation method and in-vitro anti-platelet aggregation effects of the novel conjugates, and also discloses an antithrombotic use of the novel conjugates in a rat thrombus formation model. A result shows that the three novel conjugates of carbolino-hexahydropyrazine-1,4-diketone and RGD peptide (wherein R represents Lys-Arg-Gly-Asp-Val, Lys-Arg-Gly-Asp-Phe or Lys-Arg-Gly-Asp-Ser) and their heterocyclic nucleuses (wherein R represents OH) have good antithrombotic activity and clear application prospects in antithrombotic agent preparation.
Owner:CAPITAL UNIVERSITY OF MEDICAL SCIENCES
Tetrahydroisoquinoline-3-formyl-K (GRPAK) RGDV and synthesis, activity and application thereof
The invention discloses N-(3S-6,7-dihydroxy-1,1-dimethyl-1,2,3,4-tetrahydroisoquinoline-3-formyl)-Lys (Gly-Arg-Pro-Ala-Lys)-Arg-Gly-Asp-Val and a preparation method, antithrombus activity and thrombolytic activity thereof and also discloses the effect of the compound on treatment of rats suffering from cerebral ischemia. The invention discloses application of the compound in preparation of antithrombus medicines, thrombolytic medicines and medicines for treating ischemic stroke.
Owner:北京恒润泰生医药科技有限公司
TRGD peptide-modified carbolino-hexahydropyrazine-1,4-diketones and their preparation method, antithrombotic effect and use
InactiveCN103450337AOrganic active ingredientsPeptide/protein ingredientsAntithrombotic AgentArg-Gly-Asp-Phe
The invention discloses TRGD peptide-modified carbolino-hexahydropyrazine-1,4-diketones, which are three novel conjugates of carbolino-hexahydropyrazine-1,4-diketone and TRGD peptide and are shown in the general formula I. In the general formula I, R represents Thr-Arg-Gly-Asp-Val, Thr-Arg-Gly-Asp-Phe or Thr-Arg-Gly-Asp-Ser. The invention also discloses heterocyclic nucleuses of the novel conjugates, wherein R represents OH. The invention also discloses a preparation method and in-vitro anti-platelet aggregation effects of the novel conjugates, and also discloses an antithrombotic use of the novel conjugates in a rat thrombus formation model. A result shows that the three novel conjugates of carbolino-hexahydropyrazine-1,4-diketone and TRGD peptide (wherein R represents Thr-Arg-Gly-Asp-Val, Thr-Arg-Gly-Asp-Phe or Thr-Arg-Gly-Asp-Ser) and their heterocyclic nucleuses (wherein R represents OH) have good antithrombotic activity and clear application prospects in antithrombotic agent preparation.
Owner:CAPITAL UNIVERSITY OF MEDICAL SCIENCES
Aspirin-Arg-Gly-Asp-Val conjugate, synthesis, nano structure, and application thereof as drug carrying system
InactiveCN104211763AOrganic active ingredientsPeptide preparation methodsAntithrombotic AgentAspirin
The invention relates to an aspirin-Arg-Gly-Asp-Val conjugate, synthesis, a nano structure, and an application thereof as a drug carrying system. The invention discloses a novel aspirin-Arg-Gly-Asp-Val (A-RGDV) conjugate, and also discloses a preparation method and an application thereof as an antithrombotic agent. The A-RGDV is characterized in that in the blood the A-RGDV can be selectively transferred as nano particles, when the A-RGDV nano particles arrive at the thrombus forming parts, the A-RGDV reacts with the GPIIb / IIIa receptors on the platelet surfaces, and thus aspirin is released during the process. So the A-RGDV can be used as a target drug delivery system for aspirin. A-RGDV has a strong antithrombotic activity, and has a good clinical application prospect. The structural formula of A-RGDV is represented in the description.
Owner:CAPITAL UNIVERSITY OF MEDICAL SCIENCES
1R-methyl-beta-tetrahydrocarbolineacyl-K(QRPAK)-RGDV, and synthesis, activity and application thereof
The invention discloses 1R-methyl-1,2,3,4-tetrahydro-beta-carboline-3S-acyl-Lys(Gln-Arg-Pro-Ala-Lys)-Arg-Gly-Asp-Val, a preparation method, antithrombotic activity and thrombolytic activity thereof, and application of the compound in treating rats with a 24-hour stroke. Thus the invention discloses application of the compound in preparation of antithrombotic drugs, thrombolytic drugs and drugs fortreatment of ischemic strokes. The compound has a formula shown in the description.
Owner:CAPITAL UNIVERSITY OF MEDICAL SCIENCES
The-RGDVGRPAK decapeptide, and preparation, activities and application thereof
The invention discloses The-Arg-Gly-Asp-Val-Gly-Arg-Pro-Ala-Lys decapeptide, discloses a preparation method of the The-Arg-Gly-Asp-Val-Gly-Arg-Pro-Ala-Lys decapeptide,and discloses an activity, an antithrombotic activity and a thrombus dissolving activity of the The-Arg-Gly-Asp-Val-Gly-Arg-Pro-Ala-Lys decapeptide in treating ischemic stroke. Therefore, the invention discloses application of the The-Arg-Gly-Asp-Val-Gly-Arg-Pro-Ala-Lys decapeptide to the preparation of antithrombotic and thrombolytic medicines for treating ischemic stroke.
Owner:CAPITAL UNIVERSITY OF MEDICAL SCIENCES
1R-methyl-beta-tetrahydrocarboline acyl-K(PAK)-RGDV, and synthesis, activity and application thereof
InactiveCN108948145APeptide/protein ingredientsPeptide preparation methodsAntithrombotic AgentThrombolytic drug
The present invention discloses 1R-methyl-1,2,3,4-tetrahydro-beta-carboline-3S-acyl-Lys(Pro-Ala-Lys)-Arg-Gly-Asp-Val of a formula shown in the description, discloses a preparation method of the compound, discloses the antithrombotic activity of the compound, discloses the thrombolytic activity of the compound and discloses the effect of the compound in treating a rat with a stroke of 24 hours, andthus the present invention discloses application of the compound in preparation of an antithrombotic drug, a thrombolytic drug and drugs for treating ischemic stroke drugs.
Owner:CAPITAL UNIVERSITY OF MEDICAL SCIENCES
1R-methyl-beta-tetrahydrocarbolineacyl-K(ARPAK)-RGDV, and synthesis, activity and application thereof
InactiveCN108948146APeptide/protein ingredientsPeptide preparation methodsAntithrombotic AgentMedicine
The invention discloses 1R-methyl-1,2,3,4-tetrahydro-beta-carboline-3S-acyl-Lys(Ala-Arg-Pro-Ala-Lys)-Arg-Gly-Asp-Val, a preparation method, antithrombotic activity and thrombolytic activity thereof, and application of the compound in treating rats with a 24-hour stroke. Thus the invention discloses application of the compound in preparation of antithrombotic drugs, thrombolytic drugs and drugs fortreatment of ischemic strokes. The compound has a formula shown in the description.
Owner:CAPITAL UNIVERSITY OF MEDICAL SCIENCES
The-K(KAPRG)RGDV hendeca-peptide, as well as preparation, activity and application thereof
The invention discloses The-Lys(Lys-Ala-Pro-Arg-Gly)-Arg-Gly-Asp-Val hendeca-peptide, and discloses a preparation method of the The-Lys(Lys-Ala-Pro-Arg-Gly)-Arg-Gly-Asp-Val hendeca-peptide, activity of treating ischemic stroke, antithrombus activity and thrombolytic activity. Therefore, the invention discloses application of the The-Lys(Lys-Ala-Pro-Arg-Gly)-Arg-Gly-Asp-Val hendeca-peptide in preparation of ischemic stroke treatment, antithrombus and thrombolytic medicines.
Owner:CAPITAL UNIVERSITY OF MEDICAL SCIENCES
Pentamethoxytryptophanylcarbonylpropionyl-RPAK peptide, and preparation method, activities and applications thereof
The invention discloses a pentamethoxytryptophanylcarbonylpropionyl-RPAK peptide, and a preparation method, activities and applications thereof, and concretely relates to a pentamethoxytryptophanylcarbonylpropionyl-Lys(Arg-Pro-Ala-Lys)-Arg-Gly-Asp-Val with the formula shown in the description, a preparation method thereof, an antithrombotic activity and a thrombus dissolving activity of the pentamethoxytryptophanylcarbonylpropionyl-Lys(Arg-Pro-Ala-Lys)-Arg-Gly-Asp-Val, and an application of the pentamethoxytryptophanylcarbonylpropionyl-Lys(Arg-Pro-Ala-Lys)-Arg-Gly-Asp-Val in the treatment of stroke rats. The invention also discloses an application of the pentamethoxytryptophanylcarbonylpropionyl-Lys(Arg-Pro-Ala-Lys)-Arg-Gly-Asp-Val in the preparation of antithrombotic medicines, thrombus dissolving medicines and ischemic stroke treatment medicines.
Owner:CAPITAL UNIVERSITY OF MEDICAL SCIENCES
rgd peptide-modified carboline hexahydropyrazine-1,4-dione, its preparation method, antithrombotic effect and application
InactiveCN103450334BOrganic active ingredientsPeptide preparation methodsDiketoneAntithrombotic Agent
Owner:CAPITAL UNIVERSITY OF MEDICAL SCIENCES
Imidazo pyridine acyl-KRGDV, synthesis thereof, antithrombus activity and application
Owner:CAPITAL UNIVERSITY OF MEDICAL SCIENCES
4'-oxyacetyl-APAK-7-oxyacetyl-RGDV-isoflavone, and synthesis, activity and application thereof
The invention discloses 4'-oxyacetyl-Ala-Pro-Ala-Lys-7-oxyacetyl-Arg-Gly-Asp-Val-isoflavone, a preparation method thereof, antithrombotic activity thereof, thrombolytic activity thereof, cerebral-thrombus-treating activity thereof, and free-radical-removing activity thereof. The invention discloses an application of 4'-oxyacetyl-Ala-Pro-Ala-Lys-7-oxyacetyl-Arg-Gly-Asp-Val-isoflavone to prepare antithrombotic medicines, thrombolytic medicines, cerebral-thrombus-treating medicines, and free-radical-removing medicines.
Owner:CAPITAL UNIVERSITY OF MEDICAL SCIENCES
1S-methyl-beta-tetrahydrocarbolineacyl-K(PAK)-RGDV, synthesis, activity and application thereof
The invention discloses 1S-methyl-1,2,3,4-tetrahydro-beta-carboline-3S-formyl-Lys(Pro-Ala-Lys)-Arg-Gly-Asp-Val as shown in the formula, its preparation method, its antithrombotic activity, its thrombolytic activity, and its effect of treating rats with stroke for 24 hours. Therefore, the invention discloses preparation of the 1S-methyl-1,2,3,4-tetrahydro-beta-carboline-3S-formyl-Lys(Pro-Ala-Lys)-Arg-Gly-Asp-Val in preparation of antithrombotic drugs, thrombolytic drugs and drugs for treating ischemic stroke.
Owner:CAPITAL UNIVERSITY OF MEDICAL SCIENCES
Pentamethoxytryptamine carbonylpropionyl-rpak peptide, its preparation, activity and application
ActiveCN106317189BPeptide/protein ingredientsPeptide preparation methodsAntithrombotic AgentMedicine
Owner:CAPITAL UNIVERSITY OF MEDICAL SCIENCES
Target restraint alpha Nu beta3 positive cell proliferation cyclic peptides
InactiveCN101402675BPrevent proliferationInhibit expressionPowder deliverySenses disorderCyclic peptideDisulfide bonding
The invention relates to cyclic peptides for inhibiting the proliferation of alpha v beta 3 positive cells in a target direction and the preparation and application thereof. The cyclic peptide has an amino acid sequence as follows: Cys Arg Gly Asp Val Cit Arg Leu Arg Trp Arg Lys Cys, wherein, Cys at the end of N and Cys at the end of C form a ring through a disulfide bond.
Owner:THE THIRD AFFILIATED HOSPITAL OF THIRD MILITARY MEDICAL UNIV OF PLA
GRPAKRGDV-The decapeptide, and preparation, activity and application thereof
The invention discloses Gly-Arg-Pro-Ala-Lys-Arg-Gly-Asp-Val-The decapeptide, and a preparation method and ischemic stroke treatment activity, antithrombotic activity and thrombolytic activity thereof.Thus, the invention discloses an application of the Gly-Arg-Pro-Ala-Lys-Arg-Gly-Asp-Val-The decapeptide in preparation of ischemic stroke treatment, antithrombotic and hemolytic thrombolytic drugs.
Owner:CAPITAL UNIVERSITY OF MEDICAL SCIENCES
Pentamethoxytryptophanylcarbonylpropionyl-PAK peptide, and preparation method, activities and applications thereof
The invention discloses a pentamethoxytryptophanylcarbonylpropionyl-Lys(Pro-Ala-Lys)-Arg-Gly-Asp-Val with the formula shown in the description, a preparation method thereof, an antithrombotic activity and a thrombus dissolving activity of the pentamethoxytryptophanylcarbonylpropionyl-Lys(Pro-Ala-Lys)-Arg-Gly-Asp-Val, and an application of the pentamethoxytryptophanylcarbonylpropionyl-Lys(Pro-Ala-Lys)-Arg-Gly-Asp-Val in the treatment of stroke rats. The invention also discloses an application of the pentamethoxytryptophanylcarbonylpropionyl-Lys(Pro-Ala-Lys)-Arg-Gly-Asp-Val in the preparation of antithrombotic medicines, thrombus dissolving medicines and ischemic stroke treatment medicines.
Owner:CAPITAL UNIVERSITY OF MEDICAL SCIENCES
1S-methyl-beta-tetrahydrocarbolineacyl-K(ARPAK)-RGDV, synthesis, activity and application thereof
InactiveCN110577575APeptide/protein ingredientsPeptide preparation methodsAntithrombotic AgentMedicine
The invention discloses 1S-methyl-1,2,3,4-tetrahydro-beta-carboline-3S-formyl-Lys(Ala-Arg-Pro-Ala-Lys)-Arg-Gly-Asp-Val as shown in the formula, its preparation method, its antithrombotic activity, itsthrombolytic activity, and its effect of treating rats with stroke for 24 hours. Therefore, the invention discloses application of the 1S-methyl-1,2,3,4-tetrahydro-beta-carboline-3S-formyl-Lys(Ala-Arg-Pro-Ala-Lys)-Arg-Gly-Asp-Val in preparation of antithrombotic drugs, thrombolytic drugs and ischemic stroke treatment drugs.
Owner:CAPITAL UNIVERSITY OF MEDICAL SCIENCES
Aspirin‑arg‑gly‑asp‑val conjugate, its synthesis, nanostructure and application as drug delivery system
InactiveCN104211763BOrganic active ingredientsPeptide preparation methodsAntithrombotic AgentAspirin
Aspirin‑Arg‑Gly‑Asp‑Val conjugate, its synthesis, nanostructure and application as a drug delivery system. The invention discloses a novel aspirin-Arg-Gly-Asp-Val (A-RGDV) conjugate, its preparation method and its application as an antithrombotic agent. A-RGDV is characterized in that it can be selectively transported in the blood as nanoparticles, and after reaching the site of thrombus formation, it interacts with the GPIIb / IIIa receptors on the surface of activated platelets to release aspirin. Therefore, A‑RGDV is a targeted drug delivery system for aspirin. A‑RGDV has strong antithrombotic activity and has good clinical application prospects. The following is the structural formula of A‑RGDV. .
Owner:CAPITAL UNIVERSITY OF MEDICAL SCIENCES
Pentamethoxytryptamine carbonyl propionyl-pak peptide, its preparation, activity and application
Owner:CAPITAL UNIVERSITY OF MEDICAL SCIENCES
rgdv-the-grpak decapeptide, its preparation, activity and application
The invention discloses an Arg-Gly-Asp-Val-The-Gly-Arg-Pro-Ala-Lys decapeptide and its preparation method and activity of ischemic stroke treatment, thrombus formation resistance and thrombus dissolution. The invention discloses a use of the Arg-Gly-Asp-Val-The-Gly-Arg-Pro-Ala-Lys decapeptide in preparation of drugs for treating ischemic stroke, resisting thrombus formation and dissolving thrombus.
Owner:CAPITAL UNIVERSITY OF MEDICAL SCIENCES
The-GRPAKRGDV decapeptide, and preparation method, activities and application thereof
The invention discloses a The-Gly-Arg-Pro-Ala-Lys-Arg-Gly-Asp-Val decapeptide, a preparation method thereof, and an ischemic apoplexy treatment activity, an antithrombotic activity and a thrombus dissolving activity of the decapeptide. The invention also discloses an application of the decapeptide in the preparation of ischemic apoplexy treatment, antithrombosis and thrombus dissolving medicines.
Owner:CAPITAL UNIVERSITY OF MEDICAL SCIENCES
Conjugate formed by conjugating one Arg-Gly-Asp-Val chain and two fatty alcohol chains by Asp, synthesis thereof and medical application thereof
InactiveCN101906144AHas antithrombotic activityPeptide/protein ingredientsPeptide preparation methodsEmulsionArg-Gly-Asp-Val
The invention discloses a conjugate of a peptide chain and two fatty alcohol chains, a preparation method thereof and medicinal application thereof. The conjugate is formed by conjugating one Arg-Gly-Asp-Val chain and two fatty alcohol chains by Asp and has a general formula of Arg-Gly-Asp-Val-Asp[OCH2(CH2)nCH3]2, wherein n may be 6, 8, 10 or 12. The conjugate of the invention has high oral antithrombotic activities, high self-assembling property and can be used as preparation materials for preparing medicament carries such as micro emulsion and liposome.
Owner:CAPITAL UNIVERSITY OF MEDICAL SCIENCES
4'-oxyacetyl-Ala-5-hydroxyl-7-oxyacetyl-RGDV-isoflavone, and synthesis, activity and application thereof
The invention discloses 4'-oxyacetyl-Ala-5-hydroxyl-7-oxyacetyl-Arg-Gly-Asp-Val-isoflavone, a preparation method thereof, antithrombotic activity thereof, thrombolytic activity thereof, cerebral-thrombus-treating activity thereof, and free-radical-removing activity thereof. The invention discloses an application of 4'-oxyacetyl-Ala-5-hydroxyl-7-oxyacetyl-Arg-Gly-Asp-Val-isoflavone to prepare antithrombotic medicines, thrombolytic medicines, cerebral-thrombus-treating medicines, and free-radical-removing medicines.
Owner:CAPITAL UNIVERSITY OF MEDICAL SCIENCES
KRGD peptide-modified carbolino-hexahydropyrazine-1,4-diketones and their preparation method, antithrombotic effect and use
InactiveCN103450336BOrganic active ingredientsPeptide preparation methodsAntithrombotic AgentDiketone
The invention discloses KRGD peptide-modified carbolino-hexahydropyrazine-1,4-diketones, which are three novel conjugates of carbolino-hexahydropyrazine-1,4-diketone and RGD peptide and are shown in the general formula I. In the general formula I, R represents Lys-Arg-Gly-Asp-Val, Lys-Arg-Gly-Asp-Phe or Lys-Arg-Gly-Asp-Ser. The invention also discloses heterocyclic nucleuses of the novel conjugates, wherein R represents OH. The invention also discloses a preparation method and in-vitro anti-platelet aggregation effects of the novel conjugates, and also discloses an antithrombotic use of the novel conjugates in a rat thrombus formation model. A result shows that the three novel conjugates of carbolino-hexahydropyrazine-1,4-diketone and RGD peptide (wherein R represents Lys-Arg-Gly-Asp-Val, Lys-Arg-Gly-Asp-Phe or Lys-Arg-Gly-Asp-Ser) and their heterocyclic nucleuses (wherein R represents OH) have good antithrombotic activity and clear application prospects in antithrombotic agent preparation.
Owner:CAPITAL UNIVERSITY OF MEDICAL SCIENCES
RGDV-The-GRPAK decapeptide and its preparation method, activity and use
The invention discloses an Arg-Gly-Asp-Val-The-Gly-Arg-Pro-Ala-Lys decapeptide and its preparation method and activity of ischemic stroke treatment, thrombus formation resistance and thrombus dissolution. The invention discloses a use of the Arg-Gly-Asp-Val-The-Gly-Arg-Pro-Ala-Lys decapeptide in preparation of drugs for treating ischemic stroke, resisting thrombus formation and dissolving thrombus.
Owner:CAPITAL UNIVERSITY OF MEDICAL SCIENCES
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com